These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 10636570)

  • 1. Intermittent androgen suppression. Too good to be true?
    Abrahamsson PA
    Scand J Urol Nephrol Suppl; 1999; 203():45-9. PubMed ID: 10636570
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of delayed maximal androgen blockade therapy for patients with advanced prostate cancer who fail to respond to initial androgen deprivation monotherapy.
    Takayanagi A; Masumori N; Hashimoto J; Kyoda Y; Yanase M; Tsukamoto T
    Jpn J Clin Oncol; 2010 Dec; 40(12):1154-8. PubMed ID: 20647233
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Study changes how physicians treat metastatic prostate cancer: intermittent hormone therapy not as effective as continuous hormone therapy, authors say.
    Printz C
    Cancer; 2013 Sep; 119(17):3103-4. PubMed ID: 24037668
    [No Abstract]   [Full Text] [Related]  

  • 4. Finnish multicenter study comparing intermittent to continuous androgen deprivation for advanced prostate cancer: interim analysis of prognostic markers affecting initial response to androgen deprivation.
    Salonen AJ; Viitanen J; Lundstedt S; Ala-Opas M; Taari K; Tammela TL;
    J Urol; 2008 Sep; 180(3):915-9; discussion 919-20. PubMed ID: 18635219
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intermittent androgen-deprivation therapy in prostate cancer: a critical review focused on phase 3 trials.
    Sciarra A; Abrahamsson PA; Brausi M; Galsky M; Mottet N; Sartor O; Tammela TL; Calais da Silva F
    Eur Urol; 2013 Nov; 64(5):722-30. PubMed ID: 23628492
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intermittent androgen deprivation in advanced prostate cancer.
    de Reijke TM
    Urol Res; 1997; 25 Suppl 2():S63-6. PubMed ID: 9144889
    [No Abstract]   [Full Text] [Related]  

  • 7. Variation in chromogranin A serum levels during intermittent versus continuous androgen deprivation therapy for prostate adenocarcinoma.
    Sciarra A; Monti S; Gentile V; Mariotti G; Cardi A; Voria G; Lucera R; Di Silverio F
    Prostate; 2003 May; 55(3):168-79. PubMed ID: 12692782
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Current strategies of intermittent hormone therapy in prostate cancer].
    Kaprin AD; Pavlov AIu; Ivanov SA; Gafanov RA
    Vopr Onkol; 2011; 57(2):260-4. PubMed ID: 21809677
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intermittent androgen deprivation therapy in prostate cancer: is everything so clear?
    Mottet N
    Eur Urol; 2013 Jan; 63(1):121-2; discussion 123-4. PubMed ID: 22921963
    [No Abstract]   [Full Text] [Related]  

  • 10. Androgen deprivation for prostate cancer: when and how, the good and the bad.
    Chi KN; Nguyen PL; Higano CS
    Am Soc Clin Oncol Educ Book; 2013; ():. PubMed ID: 23714494
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intermittent androgen deprivation therapy: clarity from confusion.
    Klotz L
    Eur Urol; 2013 Nov; 64(5):731-3. PubMed ID: 23866956
    [No Abstract]   [Full Text] [Related]  

  • 12. Intermittent androgen ablation as a treatment for prostate cancer.
    Wolff JM
    Front Radiat Ther Oncol; 2002; 36():66-71. PubMed ID: 11842756
    [No Abstract]   [Full Text] [Related]  

  • 13. Intermittent androgen deprivation therapy may prolong the duration of androgen dependence of well-differentiated prostate cancer.
    Kaneko Y; Maekawa S; Arakaki R; Okada Y; Terada N; Nishimura K
    Hinyokika Kiyo; 2006 Apr; 52(4):259-64. PubMed ID: 16686352
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Radiation Therapy Oncology Group P-0014: a phase 3 randomized study of patients with high-risk hormone-naive prostate cancer: androgen blockade with 4 cycles of immediate chemotherapy versus androgen blockade with delayed chemotherapy.
    Pienta KJ;
    Urology; 2003 Dec; 62 Suppl 1():95-101. PubMed ID: 14747047
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Primary androgen deprivation therapy in men with prostate cancer.
    Laufman L
    JAMA; 2009 Jan; 301(1):35; author reply 35. PubMed ID: 19126809
    [No Abstract]   [Full Text] [Related]  

  • 16. Intermittent androgen deprivation.
    Dawson NA
    Curr Oncol Rep; 2000 Sep; 2(5):409-16. PubMed ID: 11122872
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Re: Alessandro Sciarra, Per Anders Abrahamsson, Maurizio Brausi, et al. Intermittent androgen-deprivation therapy in prostate cancer: a critical review focused on phase 3 trials. Eur Urol 2013;64:722-30.
    Tombal B
    Eur Urol; 2014 Apr; 65(4):e56. PubMed ID: 24380648
    [No Abstract]   [Full Text] [Related]  

  • 18. Prostate cancer: is androgen-deprivation therapy chosen wisely?
    Villanueva MT
    Nat Rev Clin Oncol; 2014 Sep; 11(9):501. PubMed ID: 25073003
    [No Abstract]   [Full Text] [Related]  

  • 19. [Combined treatment of metastatic hormone-resistant prostate cancer].
    Kaprin AD; Gafanov RA; Al'bitskiĭ IA; Fastovets SV
    Vopr Onkol; 2009; 55(4):477-9. PubMed ID: 19947375
    [No Abstract]   [Full Text] [Related]  

  • 20. Addition of Docetaxel to Androgen Deprivation Therapy for Patients with Hormone-sensitive Metastatic Prostate Cancer: A Systematic Review and Meta-analysis.
    Tucci M; Bertaglia V; Vignani F; Buttigliero C; Fiori C; Porpiglia F; Scagliotti GV; Di Maio M
    Eur Urol; 2016 Apr; 69(4):563-573. PubMed ID: 26422676
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.